The present phase I clinical trial indicated that suicide gene therapy through stereotactic intratumoral injection of allogeneic ADSCs carrying HSV-TK gene followed by prodrug administration is safe in patients with recurrent GBM. This evidence concerns the gene TKT and glioblastoma.